Peritoneal bridging versus fascial closure in laparoscopic intraperitoneal onlay ventral hernia mesh repair: a randomized clinical trial
2020 (English)In: BJS Open, E-ISSN 2474-9842, Vol. 4, no 4, p. 587-592Article in journal (Refereed) Published
Abstract [en]
BACKGROUND: Many patients develop seroma after laparoscopic ventral hernia repair. It was hypothesized that leaving the hernial sac in situ may cause this complication.
METHODS: In this patient- and outcome assessor-blinded, parallel-design single-centre trial, patients undergoing laparoscopic intraperitoneal onlay mesh ventral hernia repair were randomized (1 : 1) to either conventional fascial closure or peritoneal bridging. The primary endpoint was the incidence of seroma 12 months after index surgery detected by CT, evaluated in an intention-to-treat analysis.
RESULTS: Between September 2017 and May 2018, 62 patients were assessed for eligibility, of whom 25 were randomized to conventional closure and 25 to peritoneal bridging. At 3 months, one patient was lost to follow-up in the conventional and peritoneal bridging groups respectively. No seroma was detected at 6 or 12 months in either group. The prevalence of clinical seroma was four of 25 (16 (95 per cent c.i. 2 to 30) per cent) versus none of 25 patients in the conventional fascial closure and peritoneal bridging groups respectively at 1 month after surgery (P = 0·110), and two of 24 (8 (0 to 19) per cent) versus none of 25 at 3 months (P = 0·235). There were no significant differences between the groups in other postoperative complications (one of 25 versus 0 of 25), rate of recurrent hernia within 1 year (none in either group) or postoperative pain.
CONCLUSION: Conventional fascial closure and peritoneal bridging did not differ with regard to seroma formation after laparoscopic ventral hernia repair.
TRIAL REGISTRATION: ClinicalTrials.gov (NCT03344575).
Place, publisher, year, edition, pages
John Wiley & Sons, 2020. Vol. 4, no 4, p. 587-592
National Category
Surgery
Identifiers
URN: urn:nbn:se:oru:diva-82530DOI: 10.1002/bjs5.50305ISI: 000536310700001PubMedID: 32463163Scopus ID: 2-s2.0-85096202958OAI: oai:DiVA.org:oru-82530DiVA, id: diva2:1435894
Funder
The Karolinska Institutet's Research Foundation
Note
Funding Agency:
Örebro University Hospital
2020-06-052020-06-052024-01-02Bibliographically approved